24/7 Wall Street
25 Sept 2026, 14:49 UTC · 2h ago
Verdict
Headline leans bullish. We score JAGX +0.40 across four claims.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+0.40moderately bullish
What the story claims
4 claims · scored −1 bearish … +1 bullish · 2 new · 2 priced in
Jaguar Health targets a New Drug Application (NDA) submission for crofelemer in microvillus inclusion disease (MVID) for Q2 2027.
Priced inno timing evidence for guidance
So whatThe company expects the supporting clinical package to be completed by year-end, marking the first major milestone before the 2027 filing.
More positive than 93% of claims this week
Continue reading
5 related stories
More positive than 65% of ticker scores this week
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
Following a reverse stock split on September 17, Jaguar Health's float has been reduced to 342,780 shares.
Newsplit occurred September 17
So whatWith a total market cap of only $5.9 million, the extreme scarcity increases the probability of high volatility regardless of fundamental news.
More positive than 78% of claims this week
Napo Pharmaceuticals and Jaguar Health secured FDA user-fee waivers for Mytesi and Canalevia-CA1, respectively.
Newreported earlier this week
So whatThese waivers reduce the immediate cash burn required for regulatory filings, slightly extending the runway before the next dilutive capital raise.
More positive than 52% of claims this week
Jaguar Health has launched Neonorm Dog, a non-prescription gastrointestinal product for dogs, via Amazon.
Priced inno timing evidence
More positive than 43% of claims this week
Which stocks this story touches
More positive than 65% of ticker scores this week
Stock is surging due to pipeline progress in rare pediatric diseases and a thin float, though dilution and net losses remain risks.
Near neutral — 92% of ticker scores this week are stronger
Mentioned only as a distribution platform for a new Jaguar Health product.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
5h ago
+0.7%
Price agrees with the score
$7.11 vs $7.06 close before publication (Sep 24) · not market-adjusted
JAGX chart →
